<DOC>
	<DOCNO>NCT00668148</DOCNO>
	<brief_summary>This multicenter study enroll approximately 185 participant metastatic advance sarcoma , assess effectiveness safety IMC-A12 monotherapy indication . Participants stratify five tier accord diagnosis : 1 . Ewing 's sarcoma/PNET 2. rhabdomyosarcoma 3. leiomyosarcoma 4. adipocytic sarcoma 5. synovial sarcoma . A total 85 patient enrol initially , 17 tier . Participants receive single agent IMC-A12 every 2 week . A treatment cycle define 6 week , radiological evaluation every cycle . Safety response initial 17 patient tier use determine whether extend enrollment target total 37 patient per tier .</brief_summary>
	<brief_title>A Five-Tier , Open-Label Study IMC-A12 Advanced Sarcoma</brief_title>
	<detailed_description>The purpose study determine progression-free survival ( PFS ) rate assess 12 week initiation IMC-A12 monotherapy , administer every 2 week participant previously-treated , advanced metastatic soft tissue Ewing 's sarcoma/PNET .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Leiomyosarcoma</mesh_term>
	<mesh_term>Sarcoma , Synovial</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive , Peripheral</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion : Histologically cytologicallyconfirmed sarcoma one follow histology : ( 1 ) Ewing 's sarcoma / PNET ; ( 2 ) rhabdomyosarcoma ; 3 ) leiomyosarcoma ; ( 4 ) adipocytic sarcoma ; ( 5 ) synovial sarcoma Has measurable disease , least one lesion ≥ 2 cm conventional measurement technique ≥ 1 cm spiral compute tomography ( CT ) scan Has least one measurable lesion locate outside previously irradiate area Has radiographic documentation disease progression within 6 month prior study entry Has relapse , refractory , and/or metastatic disease , incurable surgery , radiotherapy , conventional systemic therapy Been consider ineligible systemic chemotherapy receive least one previous regimen relapse , refractory , and/or metastatic disease Adequate hematologic function Has adequate hepatic function Has adequate coagulation function Has adequate renal function Has fasting serum glucose &lt; 120 mg/dL ULN Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation Exclusion Has uncontrolled brain leptomeningeal metastases Not recover grade ≤ 1 adverse event due agent administer 3 week prior study entry Is receive investigational agent ( ) Major surgery , hormonal therapy ( replacement ) , chemotherapy , radiotherapy , form investigational therapy within 3 week prior enrollment History treatment agent target IGFR History allergic reaction attribute compound chemical biologic composition similar IMCA12 Has poorly control diabetes mellitus Is receive therapy immunosuppressive agent Is pregnant breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Sarcoma</keyword>
	<keyword>Ewing 's sarcoma / peripheral neuroectodermal tumor ( PNET ) ;</keyword>
	<keyword>rhabdomyosarcoma ;</keyword>
	<keyword>leiomyosarcoma ;</keyword>
	<keyword>adipocytic sarcoma</keyword>
	<keyword>synovial sarcoma</keyword>
</DOC>